Semaglutide, a medication often used to treat type 2 diabetes and aid in weight loss, has been reported to cause gastrointestinal side effects in some individuals
GLP-1s alter taste perception and commonly disrupt the perception of sweetness, bitterness, fatty foods and even mouthfeel, especially during early treatment phases, says the firm, which has been conducting ongoing research into the food preferences of consumers on the weight loss and diabetes management medications
A key target is the Kv7 (KCNQ) family of voltage-gated potassium channels
The resulting impact on diet and nutrition means there is absolutely a growing opportunity in Europe for bespoke products for GLP-1 drug users, says Suketu Patel, global chief medical officer at Havas, which launched its own consultancy dedicated to GLP-1 innovation in June
The effect of growth hormone (GH) replacement on muscle strength in patients with GH-deficiency: a meta-analysis